OCUL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCUL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocular Therapeutix's change in inventory for the quarter that ended in Sep. 2024 was $0.14 Mil. It means Ocular Therapeutix's inventory declined by $0.14 Mil from Jun. 2024 to Sep. 2024 .
Ocular Therapeutix's change in inventory for the fiscal year that ended in Dec. 2023 was $-0.33 Mil. It means Ocular Therapeutix's inventory increased by $0.33 Mil from Dec. 2022 to Dec. 2023 .
Ocular Therapeutix's Total Inventories for the quarter that ended in Sep. 2024 was $2.41 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ocular Therapeutix's Days Inventory for the quarter that ended in Sep. 2024 was 144.74.
Inventory Turnover measures how fast the company turns over its inventory within a year. Ocular Therapeutix's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.63.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ocular Therapeutix's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.16.
The historical data trend for Ocular Therapeutix's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | -0.74 | -0.25 | -0.05 | -0.72 | -0.33 |
Ocular Therapeutix Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Change In Inventory | Get a 7-Day Free Trial | -0.05 | -0.05 | -0.27 | 0.03 | 0.14 |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (NAS:OCUL) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ocular Therapeutix's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 2.476 | / | 1.561 | * | 365 / 4 | |
= | 144.74 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ocular Therapeutix's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 1.561 | / | 2.476 | |
= | 0.63 |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocular Therapeutix's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 2.476 | / | 15.425 | |
= | 0.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ocular Therapeutix's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey S. Heier | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Summer Road Llc | 10 percent owner | 207 6TH STREET, WEST PALM BEACH FL 33401 |
Rabia Gurses Ozden | officer: Chief Medical Officer | C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210 |
Philip C. Strassburger | officer: General Counsel | 24 CROSBY DRIVE, BEDFORD MA 01730 |
Antony C. Mattessich | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Donald Notman | officer: Chief Financial Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Christopher G White | officer: Chief Business Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Adrienne L Graves | director | 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
Merilee Raines | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Lindstrom Richard L Md | director | 2811 WESTWOOD PL, WAYZATA MN 55391 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Patricia Kitchen | officer: Chief Operations Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Leslie J. Williams | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Seung Suh Hong | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Amarpreet Sawhney | director, 10 percent owner, officer: President and CEO | C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730 |
From GuruFocus
By Marketwired • 09-25-2024
By Marketwired • 07-10-2024
By Marketwired • 07-08-2024
By Marketwired • 08-09-2024
By GuruFocus Research • 08-07-2024
By Marketwired • 08-07-2024
By GuruFocus Research • 08-08-2024
By GuruFocus News • 11-14-2024
By Marketwired • 10-09-2024
By Marketwired • 09-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.